Foghorn Therapeutics Stock Drops Nearly 50% After Ending Collaboration With Eli Lilly
Foghorn Therapeutics (NASDAQ: FHTX) saw its stock fall nearly 50% in premarket trading after announcing significant layoffs following the termination of a collaboration with Eli Lilly. The partnership, established in 2021, was dissolved after reviewing clinical data from ongoing trials. The decision by Eli Lilly to exit the collaboration has raised concerns about Foghorn's future prospects and financial stability. As a result, investor confidence appears shaken, reflected in the sharp decline of premarket trading activity for FHTX shares. This development highlights the risks associated with biotech partnerships reliant on major pharmaceutical companies. The loss of such strategic alliances can have immediate and severe impacts on smaller firms' stock performance.
Tickers: $LLY
Topics: biotech collaboration termination layoffs